SCHEMBL6284446

SCHEMBL6284446

CNCCN1CCNC1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.51
RAB9A P51151 1/20 0.51
ALDH1A1 P00352 4/20 0.48
KDM4E B2RXH2 2/20 0.46
LMNA P02545 1/20 0.46
CREBBP Q92793 1/20 0.41
MEN1 O00255 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
POLB P06746 3/20 0.41
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
CARM1 Q86X55 1/20 0.39
PRMT6 Q96LA8 1/20 0.39
PRMT8 Q9NR22 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
MAPT P10636 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9607157 0.89 KMT2A (0.47) KMT2ARAB9AALDH1A1KDM4ELMNA
SCHEMBL9607158 0.89 KMT2A (0.47) KMT2ARAB9AALDH1A1KDM4ELMNA
SCHEMBL6287263 0.89 KMT2A (0.46) KMT2ARAB9AALDH1A1KDM4ELMNA
SCHEMBL6280206 0.87 KMT2A (0.44) KMT2ARAB9AALDH1A1KDM4ELMNA
SCHEMBL6283776 0.85 KMT2A (0.43) KMT2ARAB9AALDH1A1KDM4ELMNA
SCHEMBL471729 0.83 ALDH1A1 (0.50) KMT2ARAB9AALDH1A1KDM4ELMNA
SCHEMBL6287161 0.83 KMT2A (0.42) KMT2ARAB9AALDH1A1KDM4ELMNA
SCHEMBL22030392 0.82 ALDH1A1 (0.49) KMT2ARAB9AALDH1A1KDM4ELMNA
SCHEMBL11419796 0.82 KMT2A (0.49) KMT2ARAB9AALDH1A1KDM4ELMNA
SCHEMBL6290106 0.81 KMT2A (0.41) KMT2ARAB9AALDH1A1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3405477-B1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2023-06-07 EP disclosed
US-20230136702-A1 Inhibitors of Human Herpesviruses THE GOVERNORS OF THE UNIVERSTIY OF ALBERTA (CA) 2023-05-04 US disclosed
US-20230136702-A1 Inhibitors of Human Herpesviruses THE GOVERNORS OF THE UNIVERSTIY OF ALBERTA (CA) 2023-05-04 US disclosed
US-11135544-B2 Acidic gas absorbent, acidic gas removal method and acidic gas removal apparatus KABUSHIKI KAISHA TOSHIBA (JP) 2021-10-05 US disclosed
US-11072634-B2 Inhibitors of transglutaminases ZEDIRA GMBH (DE) 2021-07-27 US disclosed
US-20210147478-A1 INHIBITORS OF BLOOD COAGULATION FACTOR XIII ZEDIRA GMBH (DE) 2021-05-20 US disclosed
EP-3666274-A1 CARBOXAMIDE DERIVATIVES AND USE THEREOF Purdue Pharma LP (US) 2020-06-17 EP disclosed
US-20200047110-A1 ACIDIC GAS ABSORBENT, ACIDIC GAS REMOVAL METHOD AND ACIDIC GAS REMOVAL APPARATUS KABUSHIKI KAISHA TOSHIBA (JP) 2020-02-13 US disclosed
EP-3221306-B1 HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2019-11-13 EP disclosed
WO-2019201432-A1 INHIBITORS OF BLOOD COAGULATION FACTOR XIII ZEDIRA GMBH (DE) 2019-10-24 WO disclosed
WO-2006018284-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS NOVARTIS AG (CH) 2006-02-23 WO disclosed
US-6916854-B2 Heat and/or light curable films or coatings comprising polyurethanes or polyureaurethane copolymers having storage stability, used as automobile paints BASF AKTIENGESELLSCHAFT (DE) 2005-07-12 US disclosed
US-20040097642-A1 Unsaturated compounds containing carbamate terminal groups or urea terminal groups BASF AKTIENGESELLSCHAFT (DE) 2004-05-20 US disclosed
WO-2004024728-A2 PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-03-25 WO disclosed
EP-0734384-B1 3-SUBSTITUTED 1-ARYLINDOLE COMPOUNDS LUNDBECK & CO AS H (DK) 2000-08-09 EP disclosed
EP-0939077-A2 3-Substituted 1-arylindole compounds as 5-HT2 antagonists H. LUNDBECK A/S (DK) 1999-09-01 EP disclosed
US-5789404-A CENTRAL NERVOUS SYSTEM DISORDERS AND ANTISEROTONIN AGENTS H. LUNDBECK A/S (DK) 1998-08-04 US disclosed
EP-0734384-A1 3-SUBSTITUTED 1-ARYLINDOLE COMPOUNDS H. LUNDBECK A/S (DK) 1996-10-02 EP disclosed
WO-1995016684-A1 3-SUBSTITUTED 1-ARYLINDOLE COMPOUNDS H. LUNDBECK A/S (DK) 1995-06-22 WO disclosed
US-4088500-A AMIDE-ENDCAPPED HYDROPHILIC ALKYLENE OXIDE PREPOLYMER, ACID ACTIVATED CROSSLINKING AGENT WATER, FILLER, CATALYST MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1978-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230136702-A1 Inhibitors of Human Herpesviruses RPL5, RPL35, HAVCR2 KMT2A 329/4885RAB9A 2843/4885ALDH1A1 1582/4885
US-20210147478-A1 INHIBITORS OF BLOOD COAGULATION FACTOR XIII TFPI, F11, F13B KMT2A 2770/4885RAB9A 1866/4885ALDH1A1 2881/4885
US-11072634-B2 Inhibitors of transglutaminases TGM2, TGM3, TGM1 KMT2A 1259/4885RAB9A 1872/4885ALDH1A1 1469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.